MK-2870-015: A phase III study of trophoblast antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) vs treatment of physician’s choice (TPC) for previously treated metastatic gastroesophageal adenocarcinoma (GEA) Meeting Abstract
| Authors: | Wainberg, Z. A.; Van Cutsem, E.; Shitara, K.; Janjigian, Y. Y.; Oh, D. Y.; Xu, J.; Wu, S.; Bhaumik, S.; Bhagia, P.; Tabernero, J. |
| Abstract Title: | MK-2870-015: A phase III study of trophoblast antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) vs treatment of physician’s choice (TPC) for previously treated metastatic gastroesophageal adenocarcinoma (GEA) |
| Meeting Title: | ESMO Congress 2024 |
| Journal Title: | Annals of Oncology |
| Volume: | 35 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2024 Sep 13-17 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2024-09-01 |
| Start Page: | S909 |
| End Page: | S910 |
| Language: | English |
| ACCESSION: | WOS:001326612902093 |
| DOI: | 10.1016/j.annonc.2024.08.1537 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 1471TiP -- Source: Wos |
